NAFDAC approves AstraZeneca vaccine for COVID-19; What you should know

In its effort to combat the pandemic and flatten the curve, the National Agency for Food and Drug Administration and Control (NAFDAC) has approved AstraZeneca vaccine for emergency use operations.

Director-General of NAFDAC, Dr. Mojisola Adeyeye, during a live session, on Thursday, February 18, 2021, made the announcement.

Further assuring Nigerians of the agency’s commitment to protect the country, Dr. Mojisola Adeyeye noted that the vaccine has been tested to be effective, and could be stored at 2 to 8-degree centigrade.

AstraZeneca covid 19 vaccine

About the vaccine:

Research revealed that the Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, is a COVID-19 vaccine developed by Oxford University and AstraZeneca given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1.

What you should know:

  • One dosing regimen, of the vaccine, showed 90% efficacy when a half-dose was followed by a full-dose after at least one month, based on mixed trials with no participants over 55 years old.
  • Another dosing regimen showed 62% efficacy when given as two full doses separated by at least one month.

About the author

Quillcastle Nigeria

Quillcastle Nigeria is an independent premium news publisher covering tech startup news, analysis, art, lifestyle, career, and other top industry updates (especially) from Africa’s largest economy (Nigeria), and beyond.

We are on a mission to become Nigeria’s most authoritative digital news agency, publishing insightful stories on global trends to inspire, educate and inform the public at every read.

Email: quillcastleng (at)
Tel: +2348025300029

1 Comment

Click here to post a comment